RxDoctor Payments Data

Run Xue, MD

Internal Medicine · Bellevue, WANPI 1265594162

Payments from drug & device makers

$3,380in general payments, 2019–2025

Across 30 payments — averaging $112.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$816
  • Johnson & Johnson$472
  • Novo Nordisk$453
  • Lilly USA, LLC$322
  • Phathom Pharmaceuticals, Inc.$244
  • Boehringer Ingelheim$238
  • plus $834 from 7 others

What the payments were for

  • Food & beverage$3,380100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,380 in reported general payments places this provider in the 90th percentile of 2,038 internal medicine providers in Washington.

See all internal medicine providers in Washington

Medicare billing

Part B allowed, 2024
$55,509
Medicare patients
119
Services billed
530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin53$85,368
FarxigaDapagliflozin Propanediol17$25,253
JanuviaSitagliptin Phosphate12$19,723
EliquisApixaban15$18,960
OzempicSemaglutide13$11,852
VascepaIcosapent Ethyl11$8,102
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$5,301
Atorvastatin Calcium412$4,073
Losartan Potassium233$2,248
Amlodipine Besylate207$2,114
Levothyroxine Sodium199$1,887
Omeprazole70$1,686
Telmisartan37$1,656
Gabapentin82$1,589
Rosuvastatin Calcium103$1,484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$238$85,36853 claims
AstraZenecaFarxiga$816$25,25317 claims
PfizerEliquis$122$18,96015 claims
Novo NordiskOzempic$453$11,85213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,038 internal medicine providers in Washington.

Other internal medicine in Bellevue

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →